AB Science share plunges through 0.67 € support level and drops another 14.5%

Clinical calendar revision weighs on share price following GCP inspection

This morning, AB Science published a statement detailing the consequences of a Good Clinical Practice (GCP) inspection conducted by three health authorities. The company specified that the overhaul of its quality management system is now the priority of the new management, which implies a rescheduling of its clinical program milestones. In this context, the share fell 14.49% during the session, to 0.59 €, marking the worst performance in the CAC All Shares among its 320 constituents.

The decline is part of an already severe underlying trend: the share has recorded a decline of 30.55% over three months and 51.44% over one year. Tomorrow, Wednesday, September 30, the company must release its turnover and half-year 2026 results, an event that will concentrate attention on the state of its cash position and the progress of its clinical programs.

Deteriorated technical configuration, well below all moving averages

The share price of 0.59 € is trading significantly below its three reference moving averages: the 20-day MA at 0.71 € (variance of -16.90%), the 50-day MA at 0.69 € (variance of -14.49%) and the 200-day MA at 1.03 € (variance of -42.72%). The share has thus fallen below its support level at 0.67 €, a level that has now become resistance. This configuration illustrates the extent of deterioration over recent months.

The RSI at 47 remains close to the neutral zone, reflecting selling pressure without marked signs of exhaustion at this stage. Upon publication of the 2025 annual results (on May 13, 2026), the company had posted a loss of 1.6 million euros for the fiscal year and reported the temporary suspension of its clinical trials in Europe in April 2026 following questions from regulatory authorities about its internal organization. The half-year results expected tomorrow will provide an initial financial assessment under the new management.